You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: January 20, 2025

Investigational Drug Information for Vadastuximab talirine


✉ Email this page to a colleague

« Back to Dashboard


What is the drug development status for Vadastuximab talirine?

Vadastuximab talirine is an investigational drug.

There have been 5 clinical trials for Vadastuximab talirine. The most recent clinical trial was a Phase 1 trial, which was initiated on May 1st 2016.

The most common disease conditions in clinical trials are Leukemia, Myeloid, Acute, Leukemia, Myeloid, and Leukemia. The leading clinical trial sponsors are Seagen Inc., Seattle Genetics, Inc., and [disabled in preview].

There are two US patents protecting this investigational drug and fifty-three international patents.

Recent Clinical Trials for Vadastuximab talirine
TitleSponsorPhase
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaSeagen Inc.Phase 3
Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid LeukemiaSeattle Genetics, Inc.Phase 3
Study of Vadastuximab Talirine (SGN-CD33A; 33A) in Combination With Azacitidine in Patients With Previously Untreated Higher Risk MDSSeagen Inc.Phase 1/Phase 2

See all Vadastuximab talirine clinical trials

Clinical Trial Summary for Vadastuximab talirine

Top disease conditions for Vadastuximab talirine
trials011223344Leukemia, Myeloid, AcuteLeukemia, MyeloidLeukemiaLeukemia, Promyelocytic, Acute[disabled in preview]
Top clinical trial sponsors for Vadastuximab talirine
trials011223344556Seagen Inc.Seattle Genetics, Inc.[disabled in preview]

See all Vadastuximab talirine clinical trials

US Patents for Vadastuximab talirine

DrugnamePatent NumberPatent TitlePatent AssigneeEstimated Expiration
Vadastuximab talirine ⤷  Subscribe Syringe plunger assemblies W. L. Gore & Associates, Inc. (Newark, DE) ⤷  Subscribe
Vadastuximab talirine ⤷  Subscribe High concentration protein formulations with reduced viscosity Bhami's Research Laboratory, Pvt. Ltd. (Mangalore, IN) ⤷  Subscribe
>Drugname>Patent Number>Patent Title>Patent Assignee>Estimated Expiration
Showing 1 to 2 of 2 entries

International Patents for Vadastuximab talirine

DrugnameCountryDocument NumberEstimated ExpirationRelated US Patent
Vadastuximab talirine Australia AU2017207281 2036-01-11 ⤷  Subscribe
Vadastuximab talirine Australia AU2017207284 2036-01-11 ⤷  Subscribe
Vadastuximab talirine Brazil BR112018013663 2036-01-11 ⤷  Subscribe
Vadastuximab talirine Brazil BR112018013679 2036-01-11 ⤷  Subscribe
Vadastuximab talirine Canada CA3009194 2036-01-11 ⤷  Subscribe
Vadastuximab talirine Canada CA3010754 2036-01-11 ⤷  Subscribe
>Drugname>Country>Document Number>Estimated Expiration>Related US Patent
Showing 1 to 6 of 6 entries

Development Update and Market Projection for Vadastuximab Talirine

Introduction

Vadastuximab talirine, also known as SGN-CD33A, is an antibody-drug conjugate (ADC) developed by Seattle Genetics, targeting the CD33 receptor expressed on approximately 90% of acute myeloid leukemia (AML) blast cells. Here, we will delve into the development updates and market projections for this drug candidate.

Mechanism of Action

Vadastuximab talirine works by binding to the CD33 transmembrane receptor, delivering a potent cytotoxic agent, a pyrrolobenzodiazepine dimer, directly to the cancer cells. This targeted approach aims to minimize damage to healthy cells while maximizing the therapeutic effect on AML cells[5].

Clinical Trials and Development

Early Promise and Initial Trials

Initial phase Ib studies showed promising results, with a 76% overall response rate and a 60% complete remission rate when vadastuximab talirine was combined with standard 7+3 chemotherapy in newly diagnosed AML patients. These studies indicated minimal residual disease-negative remissions and suggested potential for reduced relapse rates and improved survival[5].

Clinical Holds and Resumption

In late 2016, the FDA placed clinical holds on several phase I trials of vadastuximab talirine due to the deaths of four patients who developed veno-occlusive disease after receiving the drug in combination with allogeneic stem cell transplant. However, after a comprehensive analysis and protocol amendments to enhance patient safety, the FDA lifted these holds in March 2017, allowing the resumption of two phase I trials[1].

Discontinuation of Phase 3 CASCADE Trial

Despite the initial promise, Seattle Genetics discontinued the phase 3 CASCADE trial in June 2017 due to higher rates of deaths, including fatal infections, in the vadastuximab talirine arm compared to the control arm. This decision was made after consultation with the Independent Data Monitoring Committee (IDMC) and a review of unblinded data. As a result, all clinical trials involving vadastuximab talirine were halted[3][4].

Safety Concerns

The primary safety concerns that led to the discontinuation of the trials included a higher incidence of fatal infections and overall increased mortality in patients receiving vadastuximab talirine, particularly in combination with hypomethylating agents (HMAs). These safety issues were not related to hepatotoxicity, which was a concern in earlier trials[3][4].

Market Impact and Projections

Current Market Landscape

The AML therapeutics market is expected to grow significantly, driven by the need for effective treatments, especially for elderly, relapsed, and refractory patients, as well as those with specific genetic mutations like FLT3 and IDH2. Despite the challenges and recent failures, including the discontinuation of vadastuximab talirine, the market is anticipated to expand from $406 million in 2016 to $1.5 billion by 2026, with a compound annual growth rate (CAGR) of 14.0%[2].

Impact of Vadastuximab Talirine's Discontinuation

The discontinuation of vadastuximab talirine's development has shifted focus to other pipeline candidates and existing therapies. Seattle Genetics is now emphasizing its other products, such as ADCETRIS (brentuximab vedotin), which remains a key player in the treatment of Hodgkin and anaplastic large cell lymphomas[4].

Future Market Opportunities

While vadastuximab talirine is no longer in development, the AML market is expected to diversify with the approval of multiple pipeline products in the next decade. New therapies targeting high unmet needs, such as elderly and relapsed/refractory patients, will drive market growth. The failure of vadastuximab talirine highlights the challenges in AML drug development but also underscores the ongoing need for innovative and safe therapeutic options[2].

Conclusion

Vadastuximab talirine, despite its initial promise, faced significant safety concerns that led to the discontinuation of its clinical trials. This setback is a reminder of the complexities and risks involved in cancer drug development. However, the AML therapeutics market remains poised for growth, driven by the introduction of new therapies and the ongoing need for effective treatments.

Key Takeaways

  • Mechanism of Action: Vadastuximab talirine targets CD33 receptors on AML blast cells using an antibody-drug conjugate.
  • Clinical Trials: Initial trials showed promise, but later trials were halted due to safety concerns.
  • Safety Concerns: Higher mortality rates, including fatal infections, led to the discontinuation of the phase 3 CASCADE trial.
  • Market Impact: The AML therapeutics market is expected to grow significantly despite the discontinuation of vadastuximab talirine.
  • Future Opportunities: New pipeline products with diverse mechanisms of action will drive market growth.

FAQs

  1. What is vadastuximab talirine?

    • Vadastuximab talirine is an antibody-drug conjugate targeting the CD33 receptor on AML blast cells.
  2. Why were the clinical trials for vadastuximab talirine discontinued?

    • The trials were discontinued due to higher rates of deaths, including fatal infections, in the treatment arm compared to the control arm.
  3. What were the initial results of the phase Ib trials for vadastuximab talirine?

    • The phase Ib trials showed a 76% overall response rate and a 60% complete remission rate when combined with 7+3 chemotherapy.
  4. How does the discontinuation of vadastuximab talirine affect the AML market?

    • The discontinuation shifts focus to other pipeline candidates and existing therapies, but the AML market is still expected to grow with new approvals.
  5. What are the future market projections for AML therapeutics?

    • The AML therapeutics market is projected to grow from $406 million in 2016 to $1.5 billion by 2026, driven by new therapies targeting high unmet needs.

Sources

  1. FDA Lifts Clinical Hold on Vadastuximab Talirine Trials in AML - Onclive
  2. AML therapeutics market expected to diversify by 2026 - Pharmaceutical Technology
  3. Seattle Genetics Discontinues Phase 3 CASCADE Trial of Vadastuximab Talirine - Business Wire
  4. Safety concerns sideline Seattle Genetics' cancer candidate - Biopharma Dive
  5. Vadastuximab Talirine Shows Early Promise in Newly Diagnosed Acute Myeloid Leukemia - ASCO Post

More… ↓

⤷  Subscribe

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.